Loading...
Thumbnail Image
Item

Integrating genetic polymorphisms and clinical data to develop predictive models for skin toxicity in breast cancer radiation therapy

Aguado-Flor, E.
Reyes, V. M.
Navarro, V.
Mollà, M.
Aguado-Barrera, M. E.
Altabas, M.
Azria, D.
Baten, A.
Bourgier, C.
Bultijnck, R.
... show 10 more
Citations
Google Scholar:
Altmetric:
Abstract
BACKGROUND: We aim to develop and validate predictive models for acute and late skin toxicity in breast cancer (BC) patients undergoing radiation therapy (RT). Models incorporate a genetic profile-comprising candidate single nucleotide polymorphisms (SNPs) in non-coding RNAs and previously reported toxicity-associated variants-combined with clinical variables. METHODS: The study involved 1979 BC patients monitored for two to eight years post-RT in a multi-centre study. We assessed acute (oedema/erythema) and late (atrophy/fibrosis) toxicity using logistic regression and Cox proportional hazards models. The cohort was divided into training and validation datasets. RESULTS: Six SNPs demonstrated to be predictors of acute (rs13116075, rs12565978, rs72550778 and rs7284767) and late toxicity (rs16837908 and rs61764370) either in the training or validation cohort. However, none of these SNPs were consistently associated with toxicity across both stages of analysis. The rs13116075, rs12565978 and rs16837908 were previously reported to be associated with RT toxicity. In the validation phase, SNP-based models showed limited predictive ability, with AUC values of 0.49 and c-index of 0.54 for acute and late toxicity, respectively. Models incorporating either clinical variables alone or in combination with SNPs achieved similar AUC and c-index values of ∼0.60 for acute and late toxicity, respectively. However, the combined model exhibited the highest predictive accuracy for acute and late toxicity, both in the training and the validation cohorts. CONCLUSIONS: Our findings highlight the importance of combining clinical data with genetic markers to enhance the accuracy of models predicting RT toxicity in BC.
Affiliation
Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; University of Barcelona, Barcelona, Spain. Department of Radiation Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Biostatistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain; Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, A Coruña, Spain. Institut de Recherche en Cancérologie de Montpellier, University Federation of Radiation Oncology of Mediterranean Occitanie, Université de Montpellier, INSERM U1194 IRCM, Montpellier, France. Radiation Oncology, UZ Leuven, Leuven, Belgium. Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Radiation Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Centre for Cancer Genetic Epidemiology, Dept of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, CB1 8RN, UK. Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom. University Federation of Radiation Oncology of Occitanie Méditerranée, CHU Nîmes, ICG, Rue Henri Pujol, 34000, Nîmes, France. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Unit of Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom. MAASTRO Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands. Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Area of Clinical and Molecular Genetics, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Department of Radiation Oncology, Mannheim Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Patient Advocate, Independent Cancer Patients' Voice, United Kingdom. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain; Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, A Coruña, Spain; Biomedical Network on Rare Diseases (CIBERER), 15706, Santiago de Compostela, Spain. Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom. MOX, Math Department, Politecnico di Milano, Piazza Leonardo da Vinci 32, Milan, 20133, Italy. Department of Radiation Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Radiation Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: sgutierrez@vhio.net.
Description
Date
2025
Publisher
Keywords
Type
Article
Citation
Aguado-Flor E, Reyes VM, Navarro V, Mollà M, Aguado-Barrera ME, Altabas M, et al. Integrating genetic polymorphisms and clinical data to develop predictive models for skin toxicity in breast cancer radiation therapy. Breast (Edinburgh, Scotland). 2025 Aug;82:104506. PubMed PMID: 40570703. Pubmed Central PMCID: PMC12264628. Epub 2025/06/27. eng.
Journal Title
Journal ISSN
Volume Title
Embedded videos